LNG-IUS治疗子宫内膜增生的预测性生物标志物  

Biomarkers predicting efficacy of LNG-IUS for treatment of endometrial hyperplasia

作　　者：王鹏宇 肖巍[1] 史丽娜 侯莉莉 WANG Pengyu;XIAO Wei;SHI Lina;HOU Lili(The Fourth Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150001,China)

机构地区：[1]哈尔滨医科大学附属第四医院,黑龙江哈尔滨150001

出　　处：《中国优生与遗传杂志》2022年第10期1899-1902,共4页Chinese Journal of Birth Health & Heredity

基　　金：哈尔滨医科大学附属第四医院特别资助科研项目(HYDSYTB202224)。

摘　　要：子宫内膜增生是一种常见的疾病,是由于外源性或内源性雌激素增多或孕激素的缺乏导致的子宫内膜组织的异常、非侵袭性增生。为了抑制其进展为子宫内膜癌,临床医生对子宫内膜增生保持高度警惕。现阶段治疗子宫内膜增生的方法有手术治疗和保守治疗两种,保守治疗分为全身孕激素治疗和左炔诺孕酮宫内缓释系统(LNG-IUS)。文中作者将对左炔诺孕酮宫内缓释系统治疗子宫内膜增生的疗效及优点进行论述,并对目前研究中可预测LNG-IUS治疗子宫内膜增生疗效的潜在生物标志物作一综述。Endometrial hyperplasia is a common disease, which is the abnormal and non-invasive proliferation of the endometrial tissue resulting from excess exogenous or endogenous oestrogenic stimulation or deficiency of progesterone. To halt the progression of endometrial hyperplasia, clinicians keep a high vigilance for endometrial hyperplasia. At present, there are two ways of treating endometrial hyperplasia: Surgical treatment and conservative treatment. Conservative treatment is divided into whole body progesterone therapy and levonorgestrel-releasing intrauterine system(LNG-IUS). In this paper, the efficacy and advantages of levonorgestrel-releasing intrauterine system in the treatment of endometrial hyperplasia are discussed, and the potential biomarkers that can predict the efficacy of it in the treatment of endometrial hyperplasia in current studies are reviewed.

关 键 词：左炔诺孕酮宫内缓释系统 子宫内膜增生 生物标志物 

分 类 号：R711.74[医药卫生—妇产科学]